Top Page
Archer Materials
(Sydney:AXE)
Archer Materials (AXE) vs. iShares MSCI Australia ETF (EWA)
Archer Materials Business Overview & Revenue Model
Archer Materials Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 2.31M | 2.14M | 1.50M | 973.00K | 467.66K | 238.86K | Gross Profit |
| 2.31M | 2.14M | 1.44M | 922.59K | 435.36K | 217.30K | EBIT |
| -5.50M | -4.71M | -10.40M | -14.22M | -3.20M | -2.93M | EBITDA |
| -5.94M | -5.11M | -8.66M | -14.97M | -3.17M | -2.50M | Net Income Common Stockholders |
| -6.41M | -4.80M | -9.05M | -14.12M | -7.84M | -2.82M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 16.89M | 18.78M | 24.19M | 28.17M | 8.93M | 8.11M | Total Assets |
| 19.70M | 22.89M | 27.21M | 30.17M | 19.69M | 25.26M | Total Debt |
| 23.14K | 109.31K | 9.10K | 19.75K | 30.09K | 0.00 | Net Debt |
| -761.51K | -18.10M | -23.31M | -26.44M | -6.21M | -8.11M | Total Liabilities |
| 650.37K | 1.09M | 1.21M | 746.23K | 732.71K | 717.86K | Stockholders Equity |
| 19.05M | 21.80M | 26.00M | 29.42M | 18.96M | 24.54M |
| Cash Flow | Free Cash Flow | ||||
| -4.39M | -4.99M | -3.21M | -4.44M | -2.32M | -1.56M | Operating Cash Flow |
| -4.30M | -4.79M | -3.03M | -4.30M | -2.22M | -1.50M | Investing Cash Flow |
| 4.77M | 6.98M | 2.31M | -94.83K | -262.25K | 308.35K | Financing Cash Flow |
| -170.53K | -115.82K | 64.90K | 24.62M | 606.22K | 8.61M |
Archer Materials Technical Analysis
Archer Materials Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $11.80B | 10.31 | -7.45% | 2.91% | 7.43% | -7.78% | |
53 Neutral | $70.08M | ― | -29.78% | ― | ― | 23.17% | |
| $293.64M | ― | -133.28% | ― | ― | ― | ||
| $90.49M | ― | -92.68% | ― | ― | ― | ||
| $51.97M | 3.10 | 25.65% | ― | ― | ― | ||
39 Underperform | AU$378.76M | ― | -46.55% | ― | 905.48% | 10.02% | |
33 Underperform | AU$83.24M | ― | -2298.41% | ― | 63.21% | -13.33% |
Archer Materials Corporate Events
Archer Materials Limited announced a change in the director’s interest, specifically regarding Gregory David English’s securities. The change involved the lapse of 5,000,000 unlisted options that were not exercised, impacting the director’s holdings but not altering the overall number of ordinary shares held. This update reflects the company’s ongoing compliance with ASX listing rules and provides transparency to stakeholders about changes in director interests.
Archer Materials Limited announced the cessation of 12,700,000 securities, specifically options that expired on May 31, 2025, without being exercised or converted. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and future growth potential.
Archer Materials has achieved a significant milestone by integrating its graphene field effect transistor (gFET) sensors with electrical readout circuitry on a silicon chip, marking a crucial step towards developing an at-home potassium monitor prototype. This advancement, part of a joint development project with Hylid Diagnostics, aims to create a cost-effective, small sensing product for chronic kidney disease testing, with plans to demonstrate initial testing accuracy by early 2026.
Archer Materials has entered a partnership with Paragraf Limited to advance the development of its Biochip for at-home testing of chronic kidney disease. This collaboration aims to enhance the technical progress of Archer’s blood potassium sensor, focusing on improving sensor accuracy, stability, and robustness. The partnership is expected to generate intellectual property for Archer, strengthening its position in the medical diagnostics industry and supporting future product development and clinical trials.
Archer Materials has extended its partnership with Queen Mary University of London to further develop qubit technology, a critical component of their quantum technology program. This collaboration aims to achieve key milestones in qubit development, including the ability to electrically probe and measure single electron spin states, which is essential for the readout and control of qubits. The project, costing approximately A$279,000, is expected to contribute to significant advancements in Archer’s quantum device capabilities, with implications for their positioning in the quantum computing industry.
Archer Materials Limited announced that its CEO, Simon Ruffell, will present at the Semiconductor Conference 2025, highlighting the company’s advancements in semiconductor technology. This presentation underscores Archer’s commitment to innovation in quantum computing and medical diagnostics, potentially enhancing its position in the semiconductor industry and offering significant implications for its stakeholders.
Archer Materials Limited has announced the appointment of Mr. Jake van der Hoek as the new Company Secretary, effective immediately. Mr. van der Hoek brings nearly a decade of experience in the financial services industry, with expertise in company secretarial duties and ASX Listing Rule requirements. This transition follows the resignation of Mr. Damien Connor, the current Chief Financial Officer and Company Secretary, who will assist in the transition until the end of June 2025. This change in leadership is expected to strengthen Archer’s corporate governance and operational communication with the ASX, potentially impacting its strategic positioning within the semiconductor industry.
Archer Materials has announced a significant advancement in their quantum program with the development of carbon nanospheres that exhibit long room temperature spin coherence lifetimes, reaching 230 nanoseconds. This breakthrough is expected to enhance the company’s position in the quantum technology industry, potentially offering new opportunities for stakeholders and advancing the capabilities of nanoscale device fabrication.
Archer Materials Limited has entered into a partnership with Canadian company Hylid Diagnostics to develop an at-home testing device for chronic kidney disease as part of its Biochip project. The collaboration will combine Archer’s potassium sensing technology with Hylid’s blood hemolysis sensor technology to create a prototype system that meets stringent accuracy requirements for blood potassium measurements. This partnership aims to bring affordable, lab-quality blood testing to homes, with a focus on the chronic kidney disease market in North America and Europe. The agreement enables both companies to work closely on a detailed work plan, with the initial phase focusing on producing stand-alone hemolysis sensors and integrating them with Archer’s technology.
Archer Materials Limited has appointed Dr. Simon Ruffell as its new CEO, effective immediately. Dr. Ruffell, who previously served as the company’s Chief Technology Officer, brings over 20 years of international experience in technology projects and team management. His expertise, particularly from leading roles at Microsoft and Applied Materials, positions Archer to advance its semiconductor technologies in medical diagnostics, sensing, and computing. This strategic leadership change is expected to enhance Archer’s market positioning and operational capabilities.